Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring

Area of Science:

• Cardiology
• Biomarker Research
• Clinical Chemistry

Background:

• Soluble ST2 (sST2) is a novel biomarker associated with myocardial remodeling and fibrosis.
• Previous studies in healthy individuals indicate sST2 has lower biologic variability (BV) than B-type natriuretic peptides.
• Lower BV suggests sST2 could be a superior biomarker for monitoring chronic heart failure (CHF).

Purpose of the Study:

• To investigate the biologic variability (BV) of sST2 in patients with chronic heart failure (CHF).
• To compare the BV of sST2 with N-terminal pro B-type natriuretic peptide (NTproBNP) in a CHF population.

Main Methods:

• Blood samples were collected from 50 stable CHF outpatients over six months.
• Intra-individual coefficients of variation (CVI) and reference change values were calculated using log-transformed data.
• sST2 and NTproBNP levels were analyzed to determine their respective BV.

Main Results:

• sST2 demonstrated significantly lower CVI and reference change values compared to NTproBNP at 1, 3, and 6 months.
• At 6 months, sST2 CVI was 16.41 (47%) versus NTproBNP CVI of 46.02 (128%) (p <0.001).
• These findings indicate a substantially lower BV for sST2 in CHF patients.

Conclusions:

• The biologic variability of sST2 is significantly lower than NTproBNP in patients with CHF.
• These results support the potential of sST2 as a more effective biomarker for monitoring patients with chronic heart failure.